About this Research Topic
The complex relationship between endocrine disorders and cancer development has gained increasing attention in recent years. Endocrine abnormalities, such as insulin resistance and thyroid hormone imbalances, are now recognized not only for their roles in traditional endocrine diseases but also for their significant impact on cancer risk and progression.
Meanwhile, the connection between autoimmune diseases and cancer has also been extensively studied and emphasized. Autoimmune diseases, such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), involve not only chronic inflammation and sustained immune activation but also endocrine dysfunction. These conditions create a tumor-promoting environment by altering immune responses and metabolic pathways. Studies have shown that the incidence of tumors is significantly higher in patients with autoimmune diseases, and these tumors often exhibit increased malignancy and resistance to conventional therapies.
Tumors associated with autoimmune diseases often have distinct pathological characteristics. For instance, patients with SLE are at a significantly higher risk of developing hematologic malignancies, such as non-Hodgkin’s lymphoma, due to prolonged immune stimulation and abnormal cell signaling. Similarly, in RA patients, there is a higher incidence of lung cancer and lymphoma, where chronic inflammation and autoimmune responses play key roles in tumor development and progression.
Endocrine dysfunctions further complicate this pathological landscape. For example, estrogen imbalances in SLE patients can modulate immune cell functions and thus increase cancer risk, while thyroid dysfunction in RA patients can accelerate cancer progression by altering metabolic states and immune responses. Additionally, metabolic abnormalities, such as insulin resistance and dysregulated lipid metabolism, can activate key signaling pathways, including PI3K/AKT/mTOR and JAK/STAT, which promote tumor growth and metastasis.
This Research Topic aims to explore and clarify the complex dynamics among endocrine regulation, immune responses, and metabolic pathways in the context of cancer influenced by autoimmune diseases. By delving into how these integrated mechanisms contribute to cancer progression and resistance to therapy, the ultimate goal is to pave the way for more personalized and effective precision medicine that can enhance the management of complex diseases and improve patient outcomes through a multidisciplinary research approach.
This Research Topic welcomes submissions of Original Research, Reviews, Mini-reviews, Methods, Perspectives, and Opinion articles focus but are not limited to the following subtopics:
• Endocrine Dysregulation and Tumor Progression in Autoimmune Diseases: exploring how specific endocrine dysregulations, such as abnormalities in estrogen, testosterone, and thyroid hormones, contribute to tumor initiation and progression in patients with autoimmune diseases.
• Immune-Metabolic Interactions in Cancer Development: investigating the complex interplay between immune responses and metabolic pathways in cancer development. It examines how chronic inflammation triggers metabolic disorders such as insulin resistance and lipid metabolism abnormalities, which, in turn, promote tumor initiation and metastasis.
• Key Signaling Pathways Linking Autoimmune Diseases, Endocrine Dysfunction, and Cancer: focusing on key signaling pathways, including PI3K/AKT/mTOR, JAK/STAT, and AMPK, and their roles in bridging autoimmune diseases, endocrine dysfunctions, and cancer development.
• Chronic Inflammation and Its Interplay with Endocrine and Metabolic Regulation in Cancer: delving into how chronic inflammation influences the tumor microenvironment through endocrine and metabolic regulation.
• Precision Medicine and AI-Driven Approaches Integrating Endocrine and Metabolic Profiles for Autoimmune Disease-Associated Cancers: integrating artificial intelligence with precision medicine to develop advanced algorithms for analyzing complex endocrine and metabolic data in patients with autoimmune diseases.
Meanwhile, the connection between autoimmune diseases and cancer has also been extensively studied and emphasized. Autoimmune diseases, such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), involve not only chronic inflammation and sustained immune activation but also endocrine dysfunction. These conditions create a tumor-promoting environment by altering immune responses and metabolic pathways. Studies have shown that the incidence of tumors is significantly higher in patients with autoimmune diseases, and these tumors often exhibit increased malignancy and resistance to conventional therapies.
Tumors associated with autoimmune diseases often have distinct pathological characteristics. For instance, patients with SLE are at a significantly higher risk of developing hematologic malignancies, such as non-Hodgkin’s lymphoma, due to prolonged immune stimulation and abnormal cell signaling. Similarly, in RA patients, there is a higher incidence of lung cancer and lymphoma, where chronic inflammation and autoimmune responses play key roles in tumor development and progression.
Endocrine dysfunctions further complicate this pathological landscape. For example, estrogen imbalances in SLE patients can modulate immune cell functions and thus increase cancer risk, while thyroid dysfunction in RA patients can accelerate cancer progression by altering metabolic states and immune responses. Additionally, metabolic abnormalities, such as insulin resistance and dysregulated lipid metabolism, can activate key signaling pathways, including PI3K/AKT/mTOR and JAK/STAT, which promote tumor growth and metastasis.
This Research Topic aims to explore and clarify the complex dynamics among endocrine regulation, immune responses, and metabolic pathways in the context of cancer influenced by autoimmune diseases. By delving into how these integrated mechanisms contribute to cancer progression and resistance to therapy, the ultimate goal is to pave the way for more personalized and effective precision medicine that can enhance the management of complex diseases and improve patient outcomes through a multidisciplinary research approach.
This Research Topic welcomes submissions of Original Research, Reviews, Mini-reviews, Methods, Perspectives, and Opinion articles focus but are not limited to the following subtopics:
• Endocrine Dysregulation and Tumor Progression in Autoimmune Diseases: exploring how specific endocrine dysregulations, such as abnormalities in estrogen, testosterone, and thyroid hormones, contribute to tumor initiation and progression in patients with autoimmune diseases.
• Immune-Metabolic Interactions in Cancer Development: investigating the complex interplay between immune responses and metabolic pathways in cancer development. It examines how chronic inflammation triggers metabolic disorders such as insulin resistance and lipid metabolism abnormalities, which, in turn, promote tumor initiation and metastasis.
• Key Signaling Pathways Linking Autoimmune Diseases, Endocrine Dysfunction, and Cancer: focusing on key signaling pathways, including PI3K/AKT/mTOR, JAK/STAT, and AMPK, and their roles in bridging autoimmune diseases, endocrine dysfunctions, and cancer development.
• Chronic Inflammation and Its Interplay with Endocrine and Metabolic Regulation in Cancer: delving into how chronic inflammation influences the tumor microenvironment through endocrine and metabolic regulation.
• Precision Medicine and AI-Driven Approaches Integrating Endocrine and Metabolic Profiles for Autoimmune Disease-Associated Cancers: integrating artificial intelligence with precision medicine to develop advanced algorithms for analyzing complex endocrine and metabolic data in patients with autoimmune diseases.
Keywords: Endocrine Dysregulation, Autoimmune Diseases, Cancer Progression, Immune-Metabolic Interactions, Chronic Inflammation, Signaling Pathways, Precision Medicine, Artificial Intelligence (AI)
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
